Home » Authors » Nuala Moran

Articles by Nuala Moran

Vernalis Raising £14.1 Million As It Negotiates Sale Of Company

May 7, 2003

Merck Stops Development Of Celltech PDE-4 Inhibitor

April 30, 2003

PPL Gives Up Plans On Plant To Manufacture AAT Product

April 30, 2003

Alizyme Eyes Phase III, Alliance Following Renzapride Results

April 30, 2003

Curnock Cook Investing Again After Forming New €150M Fund

April 30, 2003

UK Industry Gathers To Celebrate 50th Anniversary Of DNA Finding

April 30, 2003

Merck Stops Development Of Celltech PDE-4 Inhibitor

April 30, 2003

UK Industry Gathers To Celebrate 50th Anniversary Of DNA Finding

April 30, 2003

Curnock Cook Investing Again After Forming New €150M Fund

April 30, 2003

No Abstract

PPL Gives Up Plans On Plant To Manufacture AAT Product

April 30, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...